Les médicaments contre l’#hypertension n’augmentent pas le risque de #COVID-19
https://www.lapresse.ca/actualites/sciences/202005/01/01-5271814-les-medicaments-contre-lhypertension-naugmentent-pas-le-risque-d
Les [3] études ont porté sur deux classes de médicaments, qui sont également donnés aux personnes diabétiques. Ces médicaments se
terminent généralement en-pril, tels que lisinopril, et d’autres tels que valsartan et losartan.
Il s’agit plus particulièrement 1) des inhibiteurs de l’enzyme de conversion (#IEC) ou angiotensin converting enzyme (#ACE) inhibitors en anglais et 2) des bloqueurs des récepteurs de l’angiotensine (#BRA) ou #ARB en anglais qui étaient suspectés de stimuler un récepteur cellulaire (#ACE2 en anglais) du virus nécessaire à sa pénétration dans la cellule.
Les 3 études en question :
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. - PubMed - NCBI
https://www.ncbi.nlm.nih.gov/pubmed/32356626
Our results did not confirm previous concerns regarding a potential harmful association of ACE inhibitors or ARBs with in-hospital death in this clinical context.
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. - PubMed - NCBI
https://www.ncbi.nlm.nih.gov/pubmed/32356627
In this large, population-based study, the use of ACE inhibitors and ARBs was more frequent among patients with Covid-19 than among controls because of their higher prevalence of cardiovascular disease. However, there was no evidence that ACE inhibitors or ARBs affected the risk of COVID-19.
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. - PubMed - NCBI
https://www.ncbi.nlm.nih.gov/pubmed/32356628
We found no substantial increase in the likelihood of a positive test for Covid-19 or in the risk of severe Covid-19 among patients who tested positive in association with five common classes of antihypertensive medications.